Literature DB >> 17438331

Functional analysis of activating receptor LMIR4 as a counterpart of inhibitory receptor LMIR3.

Kumi Izawa1, Jiro Kitaura1, Yoshinori Yamanishi1, Takayuki Matsuoka1, Toshihiko Oki1, Fumi Shibata1, Hidetoshi Kumagai1, Hideaki Nakajima1, Mari Maeda-Yamamoto2, Jeffrey P Hauchins3, Victor L J Tybulewicz4, Toshiyuki Takai5, Toshio Kitamura6.   

Abstract

The leukocyte mono-Ig-like receptor (LMIR) belongs to a new family of paired immunoreceptors. In this study, we analyzed activating receptor LMIR4/CLM-5 as a counterpart of inhibitory receptor LMIR3/CLM-1. LMIR4 is expressed in myeloid cells, including granulocytes, macrophages, and mast cells, whereas LMIR3 is more broadly expressed. The association of LMIR4 with Fc receptor-gamma among immunoreceptor tyrosine-based activation motif-bearing molecules was indispensable for LMIR4-mediated functions of bone marrow-derived mast cells, but dispensable for its surface expression. Cross-linking of LMIR4 led to Lyn- and Syk-dependent activation of bone marrow-derived mast cells, resulting in cytokine production and degranulation, whereas that of LMIR3 did not. The triggering of LMIR4 and TLR4 synergistically caused robust cytokine production in accordance with enhanced activation of ERK, whereas the co-ligation of LMIR4 and LMIR3 dramatically abrogated cytokine production. Notably, intraperitoneal administration of lipopolysaccharide strikingly up-regulated LMIR3 and down-regulated LMIR4, whereas that of granulocyte colony-stimulating factor up-regulated both LMIR3 and LMIR4 in granulocytes. Cross-linking of LMIR4 in bone marrow granulocytes also resulted in their activation, which was enhanced by lipopolysaccharide. Collectively, these results suggest that the innate immune system is at least in part regulated by the qualitative and quantitative balance of the paired receptors LMIR3 and LMIR4.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17438331     DOI: 10.1074/jbc.M701100200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

1.  CD300 heterocomplexes, a new and family-restricted mechanism for myeloid cell signaling regulation.

Authors:  Agueda Martínez-Barriocanal; Emma Comas-Casellas; Simo Schwartz; Margarita Martín; Joan Sayós
Journal:  J Biol Chem       Date:  2010-10-19       Impact factor: 5.157

Review 2.  The CD300 molecules: an emerging family of regulators of the immune system.

Authors:  Francisco Borrego
Journal:  Blood       Date:  2013-01-04       Impact factor: 22.113

3.  Cutting edge: mouse CD300f (CMRF-35-like molecule-1) recognizes outer membrane-exposed phosphatidylserine and can promote phagocytosis.

Authors:  Seung-Chul Choi; Venkateswara R Simhadri; Linjie Tian; Aleksandra Gil-Krzewska; Konrad Krzewski; Francisco Borrego; John E Coligan
Journal:  J Immunol       Date:  2011-08-24       Impact factor: 5.422

4.  Characterization of leukocyte mono-immunoglobulin-like receptor 7 (LMIR7)/CLM-3 as an activating receptor: its similarities to and differences from LMIR4/CLM-5.

Authors:  Yutaka Enomoto; Yoshinori Yamanishi; Kumi Izawa; Ayako Kaitani; Mariko Takahashi; Akie Maehara; Toshihiko Oki; Reiko Takamatsu; Masunori Kajikawa; Toshiyuki Takai; Toshio Kitamura; Jiro Kitaura
Journal:  J Biol Chem       Date:  2010-09-03       Impact factor: 5.157

5.  Specific lipid recognition is a general feature of CD300 and TREM molecules.

Authors:  John P Cannon; Marci O'Driscoll; Gary W Litman
Journal:  Immunogenetics       Date:  2011-07-29       Impact factor: 2.846

6.  TIM1 is an endogenous ligand for LMIR5/CD300b: LMIR5 deficiency ameliorates mouse kidney ischemia/reperfusion injury.

Authors:  Yoshinori Yamanishi; Jiro Kitaura; Kumi Izawa; Ayako Kaitani; Yukiko Komeno; Masaki Nakamura; Satoshi Yamazaki; Yutaka Enomoto; Toshihiko Oki; Hisaya Akiba; Takaya Abe; Tadasuke Komori; Yoshihiro Morikawa; Hiroshi Kiyonari; Toshiyuki Takai; Ko Okumura; Toshio Kitamura
Journal:  J Exp Med       Date:  2010-06-21       Impact factor: 14.307

7.  Possible involvement of RasGRP4 in leukemogenesis.

Authors:  Naoko Watanabe-Okochi; Toshihiko Oki; Yukiko Komeno; Naoko Kato; Koichiro Yuji; Ryoichi Ono; Yuka Harada; Hironori Harada; Yasuhide Hayashi; Hideaki Nakajima; Tetsuya Nosaka; Jiro Kitaura; Toshio Kitamura
Journal:  Int J Hematol       Date:  2009-04-07       Impact factor: 2.490

8.  Human CD300C delivers an Fc receptor-γ-dependent activating signal in mast cells and monocytes and differs from CD300A in ligand recognition.

Authors:  Mariko Takahashi; Kumi Izawa; Jun-ichi Kashiwakura; Yoshinori Yamanishi; Yutaka Enomoto; Ayako Kaitani; Akie Maehara; Masamichi Isobe; Shinichi Ito; Toshihiro Matsukawa; Fumio Nakahara; Toshihiko Oki; Masunori Kajikawa; Chisei Ra; Yoshimichi Okayama; Toshio Kitamura; Jiro Kitaura
Journal:  J Biol Chem       Date:  2013-01-31       Impact factor: 5.157

9.  Identification and Characterization of CD300H, a New Member of the Human CD300 Immunoreceptor Family.

Authors:  Kouta Niizuma; Satoko Tahara-Hanaoka; Emiko Noguchi; Akira Shibuya
Journal:  J Biol Chem       Date:  2015-07-28       Impact factor: 5.157

10.  Negative regulation of autoimmune demyelination by the inhibitory receptor CLM-1.

Authors:  Hongkang Xi; Kenneth J Katschke; Karim Y Helmy; Paige A Wark; Noelyn Kljavin; Hilary Clark; Jeffrey Eastham-Anderson; Theresa Shek; Merone Roose-Girma; Nico Ghilardi; Menno van Lookeren Campagne
Journal:  J Exp Med       Date:  2009-12-28       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.